![]() Medicines containing omeprazole and one or more active substances are given a separate but related ATC code.įurther information on ATC codes is available from the WHO website. For fixed combinations in these ATC groups, the DDD is assigned based on dosing frequency only. A02BD08: Pylera: caps: bismuth subcitrate 0.14 g/ tetracycline 0.125 g/ metronidazole 0.125 g: 12 UD (12 caps). Here is an example of how an ATC code is applied for a medicine containing the active substance omeprazole for the treatment of acid reflux and ulcers in the gut:ĭrugs for peptic ulcer and gastro-oesophageal reflux diseaseĪll medicines containing omeprazole as a single active substance are given the ATC code A02BC01. ATC Code Brand name Dosage form Active ingredients per unit dose (UD) DDD comb. ![]() In some cases, an ATC code is partially assigned with a reduced number of elements, and in other cases an ATC code is not assigned. Where the relevant information is available, a full ATC code will have 7 elements made up of letters and numbers. Using the ATC code, active substances are classified in groups at five different levels according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. The WHO assigns ATC codes to all active substances contained in medicines based on the therapeutic indication for the medicine. The Anatomical Therapeutic Chemical (ATC) Classification is an internationally accepted classification system for medicines that is maintained by the World Health Organisation (WHO). This information may be useful when searching for individual medicines or classes of medicines. The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).The HPRA has recently commenced publishing ATC codes on the ‘Find a medicine’ webpage for each medicine. The DDD for lenvatinib is based on the treatment of renal cell carcinoma. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma. Substances which are multi-targeted without a clear main target are also classified in this group. This group comprises other protein kinase inhibitors which cannot be classified in the preceding groups. Lipid kinase inhibitors (phosphatidylinositol-3-kinase (Pi3K) inhibitors) are classified in L01EM. Substances which are multi-targeted without a clear main target are classified in L01EX. These are considered final and included in theJanuary 2018 version of the ATC/ DDD Index. Substances are classified according to their main target. The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in March 2017. This group comprises protein kinase inhibitors used for neoplastic diseases. This is recommended as a method to be used internationally for these particular agents. The consumption of the antineoplastic agents is in some countries measured in grams. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy. This is because of highly individualised use and wide dosage ranges. No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X. ![]() Radiopharmaceuticals used in the treatment of cancer are classified in V10X.ĭDDs have been established for the protein kinase inhibitors in L01E only. This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.Ĭorticosteroids for systemic use, see H02.Ĭombination products are classified in L01XY - Combinations of antineoplastic agents.ĭetoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. New search Hide text from GuidelinesL ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |